COVID-19 poses more risk than vaccines for heart inflammation: Study
A health care worker prepares a syringe with the Pfizer-BioNTech COVID-19 vaccine at a vaccination clinic in Arleta, U.S., Aug. 23, 2021. (EPA Photo)


People who have received the COVID-19 vaccine developed by Pfizer and BioNTech are at slightly increased risk of heart inflammation, but the risk is higher in patients who have been infected with the coronavirus, a study revealed Wednesday.

According to the study by the New England Journal of Medicine, among every 100,000 patients who get the vaccine, one to five will likely develop myocarditis who would not otherwise have developed it.

However, that rate is much higher – 11 per 100,000 – among people infected with the coronavirus, researchers reported based on data from Clalit Health Services, a large Israeli health maintenance organization (HMO).

The data comes days after Pfizer-BioNTech's COVID-19 vaccine became the first fully approved vaccine in the United States for people aged 16 and older, a move that could potentially persuade vaccine skeptics to get the shot.

The researchers compared adverse event rates in 884,828 vaccinated individuals and an equal number of unvaccinated people. Overall, 21 persons reported myocarditis in the vaccinated group – mostly young men – compared with six people among the unvaccinated.

Most adverse events in vaccinated people were mild, but some, such as myocarditis, are potentially serious, researchers said.

The researchers also analyzed adverse event rates in more than 240,000 infected patients. The results indicate that COVID-19 infection is itself a very strong risk factor for myocarditis, and it also substantially increases the risk of other serious adverse events, they said.

"For me this is a really terrific paper in part because it actually takes data from the same system, and tries to provide more information, not just about the potential risks of vaccination, but also the potential benefits of vaccination," said Dr. Grace Lee of Stanford University, whose editorial was published with the report.

Pfizer's vaccine, along with a rival mRNA vaccine from Moderna, came under regulatory scrutiny in several countries after some reports of cases of heart inflammation.

Israel's health ministry said in June it saw a possible link between such cases and Pfizer's COVID-19 vaccine.